Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €70.46 EUR
Change Today +3.46 / 5.16%
Volume 956.6K
UCB On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
OTC US
Frankfurt
As of 11:35 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ismail Kola Ph.D.

Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive Vice President, UCB S.A.
AgeTotal Calculated CompensationThis person is connected to 65 board members in 6 different organizations across 8 different industries.

See Board Relationships
58--

Background*

Dr. Ismail Kola, Ph.D., has been the Chief Scientific Officer and Head of New Medicines Patient Value Unit at UCB S.A., since February 2015. Dr. Kola has been an Executive Vice President of UCB SA since November 23, 2009. Dr. Kola served as President of UCB New Medicines(TM) for UCB SA since November 23, 2009. He served as the President of UCB NewMedicines at Kremers Urban Pharmaceuticals Inc. He served as Executive Vice President of UCB Newmedicines (TM) at Ucb S.A. ...

Read Full Background

Corporate Headquarters*

Allée de la Recherche, 60
Brussels, Brussels 1070

Belgium

Phone: 32 2 559 99 99
Fax: 32 2 559 99 00

Board Members Memberships*

Non Executive Director
2010-Present
Director and Member of Nominations & Corporate Governance Committee
2010-Present
Director
2010-Present
Director
2011-Present
Director and Member of Governance & Nominating Committee
2011-Present
Director and Member of Nomination & Remuneration Committee

Education*

PhD
University of Cape Town
BS
University of South Africa

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCB:BB €70.46 EUR +3.46

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Rajiv Kanishka Liyanaarchchie De Silva Chief Executive Officer, President and Director
Endo International plc
$1.1M
Rakesh Sachdev Chief Executive Officer, President and Director
Sigma-Aldrich Corporation
$1.0M
Richard Ridinger Chief Executive Officer
Lonza Group Ltd
SFr.1.3M
Victor Grifols Roura Chairman, Chief Executive Officer, President and Member of Appointments & Remuneration Committee
Grifols, S.A.
--
F. Michael Ball Chief Executive Officer, Director and Member of Science & Technology Committee
Hospira Inc.
$1.1M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.